4. 2021/8/8
4
SGLT2阻害薬の大規模臨床研究
Baseline kidney characteristics for RCTs assessing RAS blockade in CKD as well as RCTs assessing different aspects of SGLT2
inhibitors: CV safety in T2DM, kidney protection in T2DM, HF outcomes in HF patients with and without T2DM and kidney protection in
CKD patients with and without T2DM. RCTs assessing patients with and without T2DM are labeled in red. The following SGLT2 inhibitors
were tested: canagliflozin (CANVAS and CREDENCE), dapagliflozin (DECLARE, DAPA-HF and DAPA-CKD) and empagliflozin (EMPA-
REG and EMPEROR-reduced). No baseline albuminuria data were available for DAPA-HF and EMPEROR-reduced.
SGLT2阻害薬と心血管死・腎不全
Key outcomes of RCTs assessing SGLT2 inhibitorsin patients with HF or CKD. Results are presented for the full population,which in some RCTs
(DAPA-HF, DAPA-CKD andEMPEROR-reduced) was comprised of patients with T2DM andnon-diabetic individualsandseparately for diabetics and
non-diabetics. The primary combined kidney endpointin CREDENCE andDAPA-CKD consisted of CKD progression, as assessed by a doublingof
serum creatinine (CREDENCE) or ≥50% eGFR decline (DAPA-CKD), end-stage kidney disease, renal death or CV death. The endpoint of CV death or
hospitalizationfor HF was the primary endpoint in HF trials (DAPA-HF and EMPEROR-reduced). The followingSGLT2 inhibitors were tested:
canagliflozin(CREDENCE), dapagliflozin(DAPA-HFandDAPA-CKD) andempagliflozin (EMPEROR-reduced)
SGLT2阻害薬と心不全
Can J Cardiol 2021; 37: 669-673.
SGLT2阻害薬の心血管系と腎臓へのベネフィット
Current status and key future developments in the study of SGLT2 inhibitors and CV and kidney benefit. Coloured parts indicate populations in whom
cardio- and nephroprotection have been demonstratedfor SGLT2 inhibitors: dark red for high CV risk, light brown for CKD and light red for HF. Thus colours
highlight high CV risk, HF and CKD patients and their overlaps within the T2DM and the non-diabetic populations. Additionally, non-albuminuric CKD is
indicated in green whenCV and kidney benefit has been demonstratedin large clinical trials,as for non-albuminuric CKD in T2DM patients within HF and
high CV risk trials or non-diabetic patients withHF. However,no dataare available regarding CV or kidney benefit in non-diabetic patients withCKD and an
absence of HF, thus a white (non-coloured) spot is placed over patients withnon-albuminuric CKD whoare not diabetic and do not have HF. Additionally,
there is no informationon potential CV or renal benefits in T1DM patients. EMPA-REGwillexpand data from currentlyavailable trial resultsby exploring
T1DM and non-albuminuric CKD in persons without diabetes. Of note, CV and kidney benefit has been observed up tonow for populations withan
eGFR ≥20 mL/min/1.73 m2in the contextof HF and EMPA-REGwill alsoenroll CKDpatients withan eGFR ≥20 mL/min/1.73 m2
糖尿病腎症と糖尿病性腎臓病
エビデンスに基づくCKD診療ガイドライン2018
糖尿病腎症の分類
腎臓でのGLP-1受容体とSGLT2の発現
JCI 2014;124:2333-2340
GLP-1R:
輸入細動脈・血管平滑筋
傍糸球体細胞・近位尿細管
Endocrinology 2014;155:1280-1290
Monkey (Human)
JBC 2017;292:5335-5348
Nat Rev Nephrol 2017;13:605-628